oxociprofloxacin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

oxociprofloxacin: structure given in first source; ciprofloxacin metabolite [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	128242
CHEBI ID	192773
SCHEMBL ID	9686037
MeSH ID	M0166960

Synonyms (19)

Synonym
oxociprofloxacin
1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(3-oxo-1-piperazinyl)-3-quinolinecarboxylic acid
CHEBI:192773
103237-52-1
1-cyclopropyl-6-fluoro-4-oxo-7-(3-oxopiperazin-1-yl)quinoline-3-carboxylic acid
FT-0673360
3-quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(3-oxo-1-piperazinyl)-
bay-q 3542
4-oxociprofloxacin
unii-y901rq8cdm
y901rq8cdm ,
3'-oxociprofloxacin
3-quinolinecarboxylicacid, 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(3-oxo-1-piperazinyl)-
MYYZZOHRULFPOQ-UHFFFAOYSA-N
SCHEMBL9686037
DTXSID80145706
AKOS030241012
Q27294389
1-cyclopropyl-6-fluoro-4-oxo-7-(3-oxopiperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid

Research Excerpts

Pharmacokinetics

Excerpt	Reference	Relevance
" The pharmacokinetic parameters for ciprofloxacin were not significantly altered in cirrhotic patients."	( The effect of cirrhosis on the steady-state pharmacokinetics of oral ciprofloxacin. Frost, RW; Krol, G; Lasseter, KC; Lettieri, JT; Shamblen, EC, 1989)	0.28

Dosage Studied

Excerpt	Relevance	Reference
" Therefore it appears from this study that no dosage adjustment is required in patients with hepatic cirrhosis."	( The effect of cirrhosis on the steady-state pharmacokinetics of oral ciprofloxacin. Frost, RW; Krol, G; Lasseter, KC; Lettieri, JT; Shamblen, EC, 1989)	0.28

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

Role	Description
drug metabolite	null
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (5)

Class	Description
N-arylpiperazine
piperazinone
cyclopropanes	Cyclopropane and its derivatives formed by substitution.
quinolinemonocarboxylic acid	Any aromatic carboxylic acid that contains a quinoline moiety that is substituted by one carboxy substituent.
quinolone
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (2)

Pathway	Proteins	Compounds
Drug ADME	63	87
Ciprofloxacin ADME	5	13

Research

Studies (5)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	3 (60.00)	18.7374
1990's	1 (20.00)	18.2507
2000's	1 (20.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	1 (20.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	4 (80.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
ciprofloxacin Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.. ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.	9.46	5	1	aminoquinoline; cyclopropanes; fluoroquinolone antibiotic; N-arylpiperazine; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone; zwitterion	antibacterial drug; antiinfective agent; antimicrobial agent; DNA synthesis inhibitor; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; environmental contaminant; topoisomerase IV inhibitor; xenobiotic
ciprofloxacin-7-ethylenediamine ciprofloxacin-7-ethylenediamine: metabolite of ciprofloxacin; structure given in first source	4.28	4	1
bay-s 9435 sulfociprofloxacin: structure given in first source; ciprofloxacin metabolite. sulfociprofloxacin : An organosulfonic acid that is ciprofloxacin carrying a sulfo group at position 4 of the piperazine ring. It is a metabolite of ciprofloxacin.	4.28	4	1	cyclopropanes; fluoroquinolone antibiotic; N-arylpiperazine; organosulfonic acid; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone	drug metabolite; human urinary metabolite

Condition	Relationship Strength	Studies
Chronic Kidney Failure [description not available]	1.97	1
Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.	1.97	1
Kidney Diseases Pathological processes of the KIDNEY or its component tissues.	1.97	1
Cirrhosis, Liver [description not available]	1.97	1
Liver Cirrhosis Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.	1.97	1

chemdatabank.com